Media ReleasesCircadian

View All Circadian News

Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients

Melbourne, Australia January 9 2012 – Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

The Phase 1 study will examine the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumours who have no other standard treatment options both as a monotherapy and also when used in combination with other anti-angiogenic agents. Results from the trial are expected to be available in the second half of 2012.

For further information please download PDF below:

Download this document